SAN DIEGO, Jun 1, 2004 (BUSINESS WIRE) -- Pharmessen Scientific, Inc. (Other OTC: PASC.PK), a global nutraceutical and pharmaceutical research company focused on providing leading supplements and medications for better general health, announced that it has entered into an agreement with Pharmacorp Internationale S.A. for the distribution of Pharmessen's products in Central America. While terms of the agreement were not disclosed, the agreement is estimated to represent more than $1.0 million in revenue over the next two years.
"We are delighted to have a partner as prestigious and qualified as Pharmacorp as we look to accelerate Pharmessen's growth in Central America," commented Mr. George Macleod, Chief Executive Officer of Pharmessen. "Pharmacorp is a recognized name in Central America and Pharmessen's association with the company should greatly burnish our reputation as well."
The selection of Pharmacorp further increases Pharmessen's worldwide brand and product awareness and continues Pharmessen's success in partnering with market leaders on a global basis. In addition to Central America, Pharmessen recently expanded into Japan and anticipates continuing its strategic global initiatives in Europe, Asia, and the Middle East. According to Mr. Macleod, "Our unique and all natural dietary supplements, compounds, and nutraceuticals are receiving tremendous acceptance worldwide."
About Pharmessen Scientific, Inc.
Pharmessen Scientific, Inc. is a global nutraceutical and pharmaceutical company that was formed to research, develop, produce, and market pure herbal supplements and compounds. At the core of Pharmessen's business are its patented encapsulation technology and "water activation" delay processes, which in combination enable the company's products to benefit from enhanced and extended potency. Utilizing this proprietary blending formula, the company effectively combines herbal oil extracts from organically grown plants to create novel supplements and compounds. Pharmessen is presently developing new anti-microbial and biocide agents in order to improve the treatment of diseases caused by new and multi-resistant pathogens. Additional information can be found on our website, www.pharmessen.com.
Safe Harbor Statement
This release contains forward-looking statements with respect to the results of operations and business of Pharmessen Scientific, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.